Center for Medical Weight Loss review

The ordinary and multi-month offers use different terms

The Center for Medical Weight Loss lists semaglutide at $149 on a monthly plan and tirzepatide at $239. The precise medication-supply period for those monthly tiers is not publicly defined. Separate three-month offers advertise $116 and $159 monthly equivalents, corresponding to $348 and $477 per purchase. The important qualification is the published FAQ: those three-month supply options bill every ten weeks despite describing twelve weeks of medication. A shipment interval and a billing interval should not be assumed identical.

At unchanged charges, $348 every ten weeks averages about $150.80 per calendar month over a 52-week illustration, while $477 averages about $206.70. Those calculations explain the cadence rather than create monthly payment offers. The company should clarify how overlapping supply and billing are managed and how to prevent another charge. Do not apply the ten-week rule automatically to the separate monthly tier, whose cycle is not defined, or describe a package as quarterly billing simply because it is called three months.

A newer promotion needs its own schedule

The homepage also promotes every third month free, with $298 for semaglutide or $478 for tirzepatide paid upfront and advertised monthly averages around $99 and $159. The exact divisions are approximately $99.33 and $159.33. These promotional purchases should remain separate from the dedicated $348 and $477 package terms. Ask which offer applies, when it renews, and whether the ten-week billing condition also applies to the chosen promotion. A new lower total does not by itself establish a new recurring interval.

Microdose plans are another category, with a three-month minimum and advertised equivalents of $83 for semaglutide and $116 for tirzepatide. They should not replace standard-treatment prices in a comparison or be assumed equivalent at a smaller dose. The clinician needs to explain the actual prescription and rationale. A long financial term is not evidence that treatment should remain unchanged, while a lower advertised average does not establish a refund right if care must stop before the term ends.

The management company is not the treating practice

The legal information identifies be-thin, Inc. doing business as The Center for Medical Weight Loss and distinguishes its management role from the affiliated physician practice. Ask which medical group and clinician actually provide care, how follow-up works, and which pharmacy dispenses your prescription. The bundled offer includes medication and clinical support without a separate membership charge, but those inclusions should be connected to identifiable professionals rather than a brand name alone.

The service claims shipping to all 50 states and publishes pregnancy and breastfeeding exclusions, along with a BMI entry floor of 26. Those are its program criteria, not personal medical clearance or a recommendation to use medication after meeting one number. Discuss your history and existing care with the clinician. Compounded drugs are not FDA approved. Obtain the actual formulation, concentration, quantity, storage, and directions, with supply duration kept separate from the payment timing.

A long history does not settle the refund terms

The company describes a long operating history and provides a Spanish-language site, which may help some readers evaluate the service. Neither establishes a particular clinician's expertise or a guarantee of outcomes. Cancellation after approval but before shipping is described as costing $50; clarify the exact cutoff and rules after pharmacy processing. Ask how the agreement treats unused prepaid medication, future renewals, and any additional service charge rather than relying on a low advertised equivalent.

Cmwl may interest someone who wants established program infrastructure and dose-flat pricing claims. Its overlapping offer types and ten-week billing require unusual care in the financial comparison. Choose the actual prescription and written plan, then identify its full payment, renewal interval, pharmacy, clinical access, and stopping conditions. The relevant decision cannot be reduced to $116 or $159 per month, because those labels describe a purchase whose actual charge occurs on a different schedule.